TiCARos is developing very differentiated CAR-T based on our proprietary CAR-T construct designing for the treatment of solid tumors. We develop unmatched CAR-T and cell therapeutics for hematologic malignancies and solid tumors. We have Unique Proprietary CAR-T Platform & Assets for Reshaping the Current CAR-T to Make Enhanced Next-Generation Breakthrough Immunotherapeutics.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
IND approved - Staring Phase 1 June, 2023
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
About 3
Speaker
